ArticleBMC immunology2025
Serum galectin-3 level increase correlates with poor prognosis in acute coronary syndrome.
Article in BMC immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionLevels of galectin-3 (GAL-3), a pro-inflammation biomarker, are closely associated with a diagnosis of acute coronary syndrome (ACS). However, the predictive ability of GAL-3 for long-term adverse prognosis in ACS has not been well-investigated. This prospective cohort study aimed to evaluate the predictive value of GAL-3 using classification and regression tree (CART) analysis.
resultsA total of 134 patients with ACS at The Affiliated Hospital of Chengde Medical University were consecutively enrolled between January 2016 and May 2017. All included patients (102 [76.1%] male, median age, 58.18 years) completed follow-up (median, 6.5 years). The primary end-point was major adverse cardiovascular events (MACEs), including all-cause death, need for rehospitalization due to severe angina, and revascularization (re-percutaneous coronary intervention). CART results showed that GAL-3 had better prognostic ability than the other four cytokines and that the optimal GAL-3 cut-off value was 1.778 ng/mL. Kaplan–Meier analysis showed that the cumulative survival rate in the GAL-3 ≥ 1.778 ng/mL group was significantly lower than that in the GAL-3 < 1.778 ng/mL group (log-rank test, all p = 0.010). Cox regression analysis identified GAL-3 ≥ 1.778 ng/mL as an independent risk factor of long-term adverse prognosis in ACS.
conclusionSerum level of the pro-inflammation cytokine GAL-3 ≥ 1.778 ng/mL was independently associated with a high risk of MACEs in patients with ACS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.